Scientific deep-dive
Do GLP-1 Drugs Lower Obesity-Related Cancer Risk? What Meta-Analyses Show
Observational reviews link GLP-1 drugs to lower rates of several obesity-related cancers, but a meta-analysis of 48 randomized trials found little or no clear effect. Why the evidence splits, and why the comparison drug changes the answer.
GLP-1 drugs have not been shown to prevent obesity-related cancers. A meta-analysis of 48 randomized placebo-controlled trials and 94,245 participants concluded they “may have little or no effect” on that risk, though the trials were short and were not designed to measure cancer[1]. Reviews that include observational data look far more favorable, with one reporting a relative risk of 0.70 (95% CI 0.54 to 0.89)[2]. Those studies show an association, and the gap between the two kinds of evidence is the main thing to understand.
Why anyone expects a cancer effect
An International Agency for Research on Cancer working group reviewed more than 1,000 epidemiologic studies and concluded that the absence of excess body fat lowers the risk of most cancers, with sufficient evidence for sites including colon, kidney, liver, pancreatic, ovarian and postmenopausal breast cancer. On weight loss itself the group was more guarded. Observational and bariatric surgery data suggested that intentional weight loss may reduce cancer risk, but the number and quality of those studies were judged insufficient for a formal evaluation, and the group wrote that evidence in humans “remains to be established”[9].
So the hypothesis is reasonable: a drug that causes substantial weight loss could lower risk. The authors of a 78-study observational review suggest the effect, if real, may be indirect through fat loss, and a 2026 review adds possible insulin and IGF-1 signaling effects seen in preclinical studies[3][10]. Definitions also vary. One cohort counted prostate and bladder among its obesity-associated cancers[5], and that review analyzed them as cancers not known to be linked to obesity[3], so “obesity-related cancer” does not mean the same list in every paper.
What the randomized trials show
The strongest design points toward no large absolute effect in either direction, at least over the time these trials ran. In the Annals of Internal Medicine meta-analysis, GLP-1 drugs probably have little or no effect on thyroid, pancreatic, breast or kidney cancer (moderate certainty), and may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian or endometrial cancer, multiple myeloma or meningioma (low certainty). The effect on gastric cancer is very uncertain. Results held across trials at low risk of bias, in studies of semaglutide or tirzepatide, and in subgroups by follow-up, dose and weight loss. The review had no funding source[1].
The confidence intervals still leave room. For breast cancer, the estimate spans 10 fewer to 12 more cases per 10,000 people treated; for kidney cancer, 5 fewer to 13 more[1]. The authors’ caveat matters: the trials “were not designed to evaluate cancer outcomes and had short follow-up.” Latency is a known concern with short observation periods[3], so a short trial finding no difference does not rule out a later one in either direction.
What the observational reviews show
The broadest review pooled 78 observational studies and reported lower risk for 10 of 13 obesity-associated cancers. Nearly all were retrospective cohort analyses, most in people taking the drugs for type 2 diabetes[3]. A second review of 24 observational studies and randomized trials, covering 3,960,974 patients, reported the pooled relative risk of 0.70 within ten years and no significant association for thyroid cancer[2]. Its authors say prospective studies are required to validate the findings. The table sets site-level observational results beside the trial data[1][3].
| Cancer | Randomized trials | Observational studies |
|---|---|---|
| Thyroid | OR 1.37 (95% CI 0.82 to 2.31), moderate certainty | RR 1.09 (95% CI 0.98 to 1.21) |
| Kidney | OR 1.12 (95% CI 0.78 to 1.60), moderate certainty | RR 1.05 (95% CI 0.85 to 1.30) |
| Pancreatic | OR 0.84 (95% CI 0.53 to 1.35), moderate certainty | RR 0.74 (95% CI 0.67 to 0.82) |
| Colorectal | Little or no effect, low certainty | RR 0.72 (95% CI 0.66 to 0.78) |
| Liver | Little or no effect, low certainty | RR 0.73 (95% CI 0.62 to 0.85) |
| Esophageal | Little or no effect, low certainty | RR 0.77 (95% CI 0.66 to 0.91) |
| Gastric | Very uncertain | RR 0.71 (95% CI 0.60 to 0.85) |
The comparison drug changes the answer
Much of the favorable signal depends on what GLP-1 users are compared against. In the observational review, liver cancer risk looked far lower against insulin (RR 0.35, 95% CI 0.20 to 0.62). Against metformin it was essentially flat (RR 1.04, 95% CI 0.82 to 1.31), and against SGLT2 inhibitors it was slightly higher (RR 1.15, 95% CI 1.05 to 1.26). The pooled estimate was also highly inconsistent across studies (I² 93.3%)[3]. Thyroid cancer showed a similar comparator effect: the overall estimate was not significant, but the comparison with metformin was (RR 1.31, 95% CI 1.02 to 1.67)[3]. Not every site flips this way: colorectal cancer stayed lower against metformin (RR 0.74, 95% CI 0.57 to 0.96), though the reduction was smaller than against insulin (RR 0.54, 95% CI 0.44 to 0.66)[3].
A cohort of 1,651,452 people with type 2 diabetes shows the same pattern. Against insulin, GLP-1 drugs were linked to lower risk of 10 of 13 obesity-associated cancers, including pancreatic (HR 0.41, 95% CI 0.33 to 0.50) and colorectal (HR 0.54, 95% CI 0.46 to 0.64). Against metformin, none of the cancers showed a decreased risk, and kidney cancer risk was higher (HR 1.54, 95% CI 1.27 to 1.87)[6]. A 106,088-person insurance-claims cohort, also against insulin, found lower risk only for liver (HR 0.47, 95% CI 0.27 to 0.82) and pancreatic cancer (HR 0.23, 95% CI 0.11 to 0.51)[8]. One possible reason insulin comparisons look so favorable is that people who need insulin may differ in ways that models do not fully capture. A 2026 review names comparator selection among the main weaknesses of this literature[10].
People using these drugs for weight
Evidence specific to obesity is newer and has shorter follow-up. All three of these studies analyze existing health records:
- GLP-1 drugs versus diet or exercise counseling. A target trial emulation in 161,798 matched adults with obesity and no diabetes found a hazard ratio of 0.59 (95% CI 0.53 to 0.67) for obesity-associated cancers, at a median follow-up of only 2 years. The association held in subgroups except Black patients. The authors describe this as “short-term” incidence and say prospective trials are needed to confirm causality[4].
- GLP-1 drugs versus nonusers. In 86,632 matched adults in Florida health-records data, incidence of 14 cancers was 13.6 versus 16.4 per 1,000 person-years (HR 0.83, 95% CI 0.76 to 0.91). Endometrial (HR 0.75), ovarian (HR 0.53) and meningioma (HR 0.69) risk looked lower, while kidney cancer leaned the other way (HR 1.38, 95% CI 0.99 to 1.93)[5].
- Semaglutide or tirzepatide versus surgery or other drugs. In a TriNetX analysis, therapeutic-dose use was linked to less colorectal cancer than bariatric surgery (HR 0.72, P = .038) or other weight-loss medications (HR 0.68, P = .008), and less pancreatic cancer than surgery (HR 0.63, P = .041). Use at any dose showed no significant differences[7]. A result that appears in only one dose grouping, with two of its three P values near the usual threshold, is a reason for caution.
The screening side of the colorectal question is covered in our review of colorectal cancer, body weight and screening.
Why the observational numbers may overstate a benefit
A 2026 review lists the main threats: residual confounding, comparator selection, surveillance bias and insufficient follow-up[10]. The 78-study review offers its own warning signs. Lower risk also appeared for cancers not classed as obesity-related there, including lung (RR 0.72, 95% CI 0.64 to 0.81) and prostate (RR 0.82, 95% CI 0.73 to 0.92). The authors suggest smoking cessation as a possible explanation for lung cancer, yet they say reductions with no clear justification, such as melanoma, highlight their concerns about bias. Lower-quality studies and conference abstracts tended to show stronger effects for some sites. Data on dose, duration and adherence were lacking[3].
The same databases also recur across this literature. The diabetes cohort above, the 2-year emulation and the surgery comparison all came from TriNetX[4][6][7], so they are not fully independent confirmations of one another, even though their results look similar.
Kidney cancer is one to keep watching
Kidney cancer risk was not significantly elevated in the pooled trials or the observational review[1][3]. The type 2 diabetes cohort found higher risk against metformin but lower risk against insulin (HR 0.76, 95% CI 0.64 to 0.91)[6], and the estimate against nonusers in the obesity cohort was borderline[5]. That inconsistency does not establish harm. It does show that a favorable headline can hide an open question about one cancer site.
What to raise with a prescriber
- Why you are taking the drug. The 2026 review concludes GLP-1 drugs should be prescribed for approved metabolic indications and not specifically for cancer prevention or treatment[10]. That makes the established reasons for treatment the ones to weigh.
- Your screening schedule. Ask which cancer screenings you are due for, and do not treat a GLP-1 prescription as a reason to delay one.
- Your thyroid history. The separate question of the boxed warning, medullary thyroid carcinoma and the rodent data is covered in our thyroid and cancer risk review. Tell your prescriber about any personal or family history.
- A past cancer diagnosis. These studies mostly address new cancers in people without a prior diagnosis. If you have been treated for cancer, our action plan for survivors covers coordinating with your oncology team.
Frequently Asked Questions
References
- 1.Ko A, Chang YC, Bahar F, et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Ann Intern Med. 2026. PMID: 41359966.
- 2.Ateiwi YA, Mahmood R, Wong HJ, et al. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026. PMID: 41722869.
- 3.Lalani I, Nambayan R, Carbonell C, et al. Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis. Cancer Control. 2026. PMID: 42677883.
- 4.Hsu AH, Ramirez PT, Chang YH, et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Ann Oncol. 2026. PMID: 42252247.
- 5.Dai H, Li Y, Lee YA, et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncol. 2025. PMID: 40839273.
- 6.Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024. PMID: 38967919.
- 7.Bitar ER, Besir K, Cummins KC, et al. Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs. J Gastrointest Surg. 2026. PMID: 42447648.
- 8.Rashid Z, Woldesenbet S, Khalil M, et al. Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists. J Gen Intern Med. 2026. PMID: 41749007.
- 9.Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer: Viewpoint of the IARC Working Group. N Engl J Med. 2016. PMID: 27557308.
- 10.Raja NP, Kandagari N. GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far. Curr Oncol Rep. 2026. PMID: 42645635.
Related research
Tirzepatide vs GLP-1s for Heart Outcomes: What Meta-Analyses Show
Pooled analyses have not shown that tirzepatide protects the heart better than GLP-1 drugs. Here is what each meta-analysis compared, why their answers differ, and how conflicting real-world studies fit in.
9 min read
GLP-1 During Active Chemotherapy: What the Evidence Shows
Active chemotherapy commonly causes both weight gain (steroids, antiemetics) and weight loss (cachexia). GLP-1 receptor agonists in active treatment are usually deferred to post-treatment but case-by-case use exists. We review the published evidence.
11 min read
GLP-1 for Breast Cancer Survivors on Tamoxifen / Letrozole
Breast cancer survivors on AI or tamoxifen often face weight gain and metabolic syndrome. GLP-1 receptor agonists are safe with endocrine therapy. We review the absence of drug interaction, the SELECT MACE benefit in this population, and the practical onco-endocrinology pathway.
11 min read
Do Peptides Cause Cancer? The IGF-1 & Angiogenesis Question
No human study has shown therapeutic peptides cause cancer — but long-term safety data is absent. We map the IGF-1 and BPC-157/VEGFR2 angiogenesis concerns honestly.
10 min read
Does GLP-1 Cause Cancer? MTC, Pancreatic Evidence (2026)
The semaglutide thyroid cancer (MTC) boxed warning comes from rodent studies not replicated in humans, and large cohorts found no pancreatic cancer signal. GLP-1s are still contraindicated with MEN2 or a personal or family MTC history.
13 min read
GLP-1 Cancer Fears: Pancreatic vs Thyroid (MTC) Evidence
“Does Ozempic cause cancer” is two fears about two organs. Pancreatic cancer: the 2011 hypothesis was not borne out — cohort data found no increase, some lower rates. Thyroid/MTC: a real rodent signal behind a precautionary boxed warning, relevant mainly with MTC/MEN 2 history.
11 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $299/mo
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $69/mo
+ required membership
CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $129/mo
“starting at” price